New Therapeutics for Ulcerative Colitis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33502898.
- Also identified by DOI 10.1146/annurev-med-052919-120048.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.
Medical subject headings
- Anti-Ulcer Agents
- Colitis, Ulcerative
- Fecal Microbiota Transplantation
- Hyperbaric Oxygenation
- Immunologic Factors
- Janus Kinase Inhibitors
- Sphingosine 1 Phosphate Receptor Modulators